Clinical Trials Logo

Filter by:
NCT ID: NCT00632736 Completed - Parkinson Disease Clinical Trials

An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease

Start date: February 2004
Phase: Phase 3
Study type: Interventional

To evaluate the safety profile of ropinirole XL during long-term treatment in subjects with early and advanced Parkinson's disease

NCT ID: NCT00631371 Completed - Clinical trials for Renal Cell Carcinoma

Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects

INTORACT
Start date: April 2008
Phase: Phase 3
Study type: Interventional

Primary objective: Comparison of independently assessed progression free survival (PFS) in subjects administered Bevacizumab + Temsirolimus vs. those administered Bevacizumab + Interferon-Alfa. Secondary objectives: safety, Investigator assessed PFS, objective response rate (independently assessed), and overall survival.

NCT ID: NCT00629642 Completed - Multiple Sclerosis Clinical Trials

Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis

SONIC
Start date: March 14, 2008
Phase: Phase 4
Study type: Interventional

A clinical study to evaluate the efficacy and safety of solifenacin in patients with bladder symptoms due to spinal cord injury or multiple sclerosis

NCT ID: NCT00627640 Completed - Clinical trials for Idiopathic Parkinson's Disease

Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa

SETTLE
Start date: February 2009
Phase: Phase 3
Study type: Interventional

Parkinson's Disease is a major neurodegenerative disorder in which there is a progressive loss of dopamine-containing neurons. The understanding that PD is a syndrome of dopamine (DA) deficiency led to the introduction in the clinical practice of L-dopa, a precursor of DA that crosses the blood brain barrier, and also to the use of selective inhibitors of MAO-B, the major DA metabolising enzyme in man. Safinamide is an inhibitor of MAO-B. This is a phase III trial to evaluate the efficacy and safety of safinamide (50 and 100 mg p.o. q.a.m.) compared to placebo as add-on therapy to a stable dose to levodopa in subjects with advance idiopathic Parkinson's Disease. The principal efficacy measure is the increase in mean daily "on" time during the 18-hr diary recording period.

NCT ID: NCT00624351 Completed - Clinical trials for Systemic Lupus Erythematosus

Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease

Start date: January 2008
Phase: Phase 2
Study type: Interventional

The primary objective of the study is to assess the dose response and the dose frequency of epratuzumab in patients with SLE.

NCT ID: NCT00623194 Completed - Diabetes Clinical Trials

Safety Follow-up on Children and Adolescents With Type 1 Diabetes Treated With Insulin Detemir. An Extension to Trial NN304-1689

Start date: February 2008
Phase: Phase 3
Study type: Interventional

This trial is conducted in Europe. The aim of this research is to assess the safety of continuous treatment with insulin detemir following participation in trial NN304-1689 (NCT00435019) on antibody development.

NCT ID: NCT00622869 Completed - Clinical trials for Liver Transplantation

Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients

RAD
Start date: January 2008
Phase: Phase 3
Study type: Interventional

This trial was designed to address important issues that impact recipients of liver allografts as well as clinicians, ie, renal function, reduction or discontinuation of tacrolimus early post-transplantation, and progression rate of fibrosis in hepatitis C virus (HCV) positive patients.

NCT ID: NCT00622284 Completed - Clinical trials for Diabetes Mellitus, Type 2

Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes

Start date: February 2008
Phase: Phase 3
Study type: Interventional

The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (5.0 mg daily) compared to glimepiride given for 104 weeks as add-on therapy to preferably > 1500 mg metformin in patients with type 2 diabetes mellitus with insufficient glycaemic control

NCT ID: NCT00621855 Completed - Coronary Disease Clinical Trials

RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome

Start date: March 2008
Phase: Phase 2
Study type: Interventional

The purpose of this trial is to evaluate the safety and indicators of efficacy of up to 4 doses of orally administered dabigatran etexilate, administered twice daily, compared to placebo when given in addition to dual antiplatelet treatment in patients with an index event (MI) at high risk for new ischaemic cardiovascular events.

NCT ID: NCT00621504 Completed - Bacterial Pneumonia Clinical Trials

Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia

CAP
Start date: January 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether ceftaroline is effective and safe in the treatment of Community-Acquired Pneumonia